Drug Delivery Business

Tandem Diabetes Care reports positive findings for Control-IQ in low-bolusing youths

Tandem Diabetes Care (Nasdaq:TNDM) has shared new findings supporting the use of its Control-IQ technology in type 1 diabetes ...
Business Wire

Tandem Diabetes Care Announces Presentations Demonstrating Positive Real-World Improvements with Control-IQ Technology Across Diverse Populations

SAN DIEGO, Calif.--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today presented positive real-world data from ongoing use of ...
Nasdaq

Tandem Diabetes Care Announces Health Canada Approval of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced Health Canada approval of the t:slim X2™ insulin ...
Hosted on MSN

FDA clears Tandem’s Control-IQ+ technology for type 2 diabetes

The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin delivery algorithm, for use in individuals aged 18 and above with type 2 ...
Nasdaq

Tandem Diabetes Care Announces FDA Clearance of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology

Automated Insulin Dosing Software First to Receive New Classification by FDA All in-warranty t:slim X2 pump users in the United States will have the option to add the new feature free of charge via ...